science
Supreme Court Declines Review of Medicare Drug Price Negotiation Lawsuits
The U.S. Supreme Court declined to hear challenges to the Medicare drug price negotiation program. The Maryland Prescription Drug Affordability Board agreed to set an upper payment limit for Ozempic. The White House expanded its TrumpRx discount platform with more than 600 generic drugs.
May 19, 9:28 AM·1m read1 source
usatoday.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
U.S. Supreme Court declined to take up lawsuits filed by several pharmaceutical companies against the Medicare drug price negotiation program. The court did not provide a reason for its decision. The companies had already lost their appeals in lower courts.
The Maryland Prescription Drug Affordability Board agreed to set an upper payment limit for Ozempic.
The White House announced an expansion of its TrumpRx prescription drug discount platform, adding more than 600 generic drugs. The expansion includes partnerships with Mark Cuban's Cost Plus Drug Company, Amazon Pharmacy, and GoodRx.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
